Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Stock Information | RedChip

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS)


$4.5300
-0.4600 ( -8.49% ) 612.3K

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Market Data


Open


$4.5300

Previous close


$4.9900

Volume


612.3K

Market cap


$302.65M

Day range


$4.5300 - $5.0070

52 week range


$1.3000 - $10.0000

SEC Filings


Form Type Description Pages Date
8-k 8K-related 14 Jan 23, 2024
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023
4 Insider transactions 1 Dec 08, 2023

Latest News